Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc. | exh_311.htm |
| EX-21.1 - EXHIBIT 21.1 - Anika Therapeutics, Inc. | exh_211.htm |
| EX-10.6A - EXHIBIT 10.6A - Anika Therapeutics, Inc. | exh_106a.htm |
| EX-10.3A - EXHIBIT 10.3A - Anika Therapeutics, Inc. | exh_103a.htm |
| EX-10.1A - EXHIBIT 10.1A - Anika Therapeutics, Inc. | exh_101a.htm |
| 10-K - FORM 10-K - Anika Therapeutics, Inc. | f10k_022417p.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-06275, 333-66831, 333-79047, 333-58264, 333-110326, 333-160102, 333-176103 and 333-190597) of Anika Therapeutics, Inc. of our report dated February 24, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 24, 2017